Why is GE HealthCare Technologies Inc. stock rising?
CE marking for Photonova Spectra photon-counting CT is expected in H2 2026, opening European commercialization.
Flyrcado customer onboarding is expected to drive increased utilization in H2 2026, supporting the radiopharmaceutical ramp.
FDA clearance for GE HealthCare's premium anesthesia device is expected in H2 2026, enabling a U.S. launch.
The Catholic Health enterprise agreement has remaining orders to convert after Q2 2026, creating a multi-year equipment and services pipeline.
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for GE HealthCare Technologies Inc. and 4,900+ companies.